title: Micro stent implantation in patients with acute myocardial infarction without anticoagulation: clinical experience with two different antithrombotic protocols.
abstract: The 4-week outcome following Micro stent implantation for acute myocardial infarction was assessed with the use of two different antithrombotic regimens. The patients were postprocedurally treated with acetyl salicylic acid (ASA) and heparin for 24-48 h (Group I; n = 52), or ASA and ticlopidine plus abciximab if indicated (Group II; n = 52). Stent implantation was successful in 49 patients (94%) of group I and in 46 patients (89%) of group II (NS). Subacute stent thrombosis occurred in nine patients (17%) of group I and in 1 patient (2%) of group II (P < 0.05). There were no significant differences in the rates of mortality, coronary bypass operation, or vascular complications. Micro stent implantation in acute myocardial infarction is highly effective and associated with a low risk for subacute stent thrombosis if the patients are postprocedurally treated with ASA and ticlopidine plus abciximab if indicated.
authors.affiliation: Department of Cardiology, Leiden University Hospital, The Netherlands. Oemrawsingh@cardio.azl.nl
authors.forename: P V
authors.initials: PV
authors.lastname: Oemrawsingh
authors.forename: M J
authors.initials: MJ
authors.lastname: Schalij
authors.forename: W
authors.initials: W
authors.lastname: Udayachalerm
authors.forename: E E
authors.initials: EE
authors.lastname: van der Wall
authors.forename: A V
authors.initials: AV
authors.lastname: Bruschke
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D019917:Blood Vessel Prosthesis Implantation; D017023:Coronary Angiography; D001026:Coronary Artery Bypass; D003328:Coronary Thrombosis / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000601:surgery; D004359:Drug Therapy, Combination; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000517:prevention & control / Q000601:surgery; D011475:Prosthesis Failure; D012008:Recurrence; D012086:Reoperation; D012189:Retrospective Studies; D015607:Stents; D015912:Thrombolytic Therapy; D013988:Ticlopidine / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D006493:Heparin; D013988:Ticlopidine; D001241:Aspirin; D000077284:Abciximab